


Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended): A method for the treatment of neurodegenerative diseases comprising administering an effective amount of a compound of formula (I) to a human patient in need thereof:



(I)

wherein X represents OH, (C₁₋₅) alkoxy, NH₂, NH-C₁₋₅-alkyl, or N(C₁₋₅ alkyl)₂;


R₁ is a residue derived from any of the amino acid Phe, Tyr, or Trp, ~~or Pro~~, each of which may optionally be substituted by a (C₁₋₅) alkoxy groups, a (C₁₋₅) alkyl group or a halogen atom, ~~and~~ or a residue derived from Ala, Val, Leu, or Ile;

R₂ is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, ~~Pro~~, Glu, Gln, ~~pGlu~~, Asp, Leu or Asn;

R₃-and R₄ independently represent H, OH, (C₁₋₅) alkyl, or (C₁₋₅) alkoxy, provided that R₃ and R₄ are not both OH or (C₁₋₅) alkoxy;

R₅ represents H, OH, (C₁₋₅) alkyl or (C₁₋₅) alkoxy;

and wherein R₀ represents a group of the formula



wherein Y represents -CO-, -CH₂CO-, -CH₂CH₂CO-, -CH₂CH₂CH₂CO-, -CH=CH-CO or -OCH₂CO-, and wherein Z represents a halogen atom, a trifluormethyl group, (C₁₋₄) alkoxy group, (C₁₋₄) alkyl group; or wherein two neighbouring substituents may form a (C₁₋₃) alkylendioxy group; and wherein n is 0 or an integer of from 1 to 5;
or pharmaceutically acceptable salts thereof;

or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The method according to claim 1, wherein R₁ is a residue derived from any of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted by a (C₁₋₅) alkoxy group, a (C₁₋₅)alkyl group or a halogen atom, or a residue derived from the amino acid Ile.

3. (Previously presented) The method according to claim 2, wherein R₁ is a residue derived from Phe which may optionally be substituted by a (C₁₋₅) alkoxy groups, a (C₁₋₅) alkyl group or a halogen atom.

4. (previously presented) The method according to claim 1, wherein X is (C₁₋₅)alkoxy, NH₂, NH-C₁₋₅-alkyl, or N(C₁₋₅ alkyl)₂.

5. (previously presented) The method according to claim 1, wherein R₂ is a residue derived from the amino acid Gly or Ile.

6. (previously presented): The method according to claim 1, wherein R₀ is a cinnamoyl moiety.

7. (previously presented): The method according to claim 1, wherein the compound of formula (I) is a cinnamoyl-glycyl-L-phenylalanyl-L-prolinamide, cinnamoyl-isoleucyl-phenylalanyl-L-proline ethylamide, cinnamoyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.